PHILADELPHIA and VANCOUVER, British Columbia, May 15, 2024 (GLOBE NEWSWIRE) --BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announced it has entered into securities purchase agreements with healthcare-focused institutional investors and a certain existing investor and a director of the Company for the purchase and sale of 2,402,935 common shares of the Company (or pre-funded warrants in lieu thereof) and warrants to purchase up to an aggregate of 2,402,935 common shares of the Company at a combined purchase price per share (and accompanying warrant) of $2.00 for the institutional investors and $2.215 for the existing investor and director of the Company for aggregate gross proceeds of approximately $5.0 million before deducting placement agent fees and other offering expenses (the “Offering”).

费城和温哥华，不列颠哥伦比亚省，2024年5月15日（环球通讯社）--BriaCell Therapeutics Corp.（纳斯达克：BCTX，BCTXW）（TSX：BCT）（“BriaCell”或“公司”），一家开发新型免疫疗法以改变癌症护理的临床阶段生物技术公司，今天宣布，它已经与以医疗保健为重点的机构投资者和公司的某位现有投资者和董事签订了证券购买协议，购买和出售公司的2402935股普通股（或代替其的预付认股权证），并以每股2.00美元的合并购买价格（和附带认股权证）购买公司总计2402935股普通股在扣除配售代理费和其他发行费用（“发行”）之前，机构投资者的总收益约为500万美元，现有投资者和公司董事的总收益约为2.215美元。

The warrants will have an exercise price of $2.11 per share, will become exercisable six months from the date of issuance and will expire five years from the initial exercise date. The closing of the Offering is expected to take place on or about May 17, 2024, subject to the satisfaction of customary closing conditions..

认股权证的行权价格为每股2.11美元，自发行之日起六个月可行权，自首次行权之日起五年到期。本次发行的交割预计将于2024年5月17日左右进行，但须符合惯例交割条件。。

The gross proceeds of the Offering will be approximately $5.0 million before deducting placement agent fees and other estimated Offering expenses payable by the Company. The Company intends to use the net proceeds from this Offering for working capital and general corporate purposes including, but not limited to, research and development studies, including the Phase 3 pivotal study in advanced breast cancer, and the patent and legal costs associated therewith, potential repurchase of certain of our issued shares and warrants and for general working capital purposes..

在扣除配售代理费和公司应付的其他预计发行费用之前，本次发行的总收益约为500万美元。公司打算将本次发行的净收益用于营运资本和一般公司目的，包括但不限于研发研究，包括晚期乳腺癌的第三阶段关键研究，以及与之相关的专利和法律费用，可能回购我们某些已发行的股份和认股权证，以及用于一般营运资本目的。。

A.G.P./Alliance Global Partners is acting as sole placement agent for the Offering.

A、 G.P./Alliance Global Partners担任此次发行的独家配售代理。

This Offering is being made pursuant to an effective shelf registration statement on Form S-3 (File No. 333-276650) previously filed with the U.S. Securities and Exchange Commission (the “SEC”) on January 22, 2024 and declared effective on January 31, 2024. A prospectus supplement and accompanying base prospectus describing the terms of the proposed offering will be filed with the SEC, and will be available on the SEC’s website located at http://www.sec.gov.

本次发行是根据S-3表格（文件号333-276650）上的有效货架登记声明进行的，该表格先前于2024年1月22日提交给美国证券交易委员会（“SEC”），并于2024年1月31日宣布生效。描述拟议发售条款的补充招股说明书和随附的基本招股说明书将提交给美国证券交易委员会，并可在美国证券交易委员会的网站上查阅http://www.sec.gov.

Electronic copies of the prospectus supplement may be obtained, when available, from A.G.P./Alliance Global Partners, at address 590 Madison Avenue, 28th Floor, New York, NY 10022, by telephone at (212) 624-2060, or by email at prospectus@allianceg.com. The Offering may also be conducted on a private placement basis in Canada in reliance upon available exemptions from the prospectus requirements of applicable Canadian securities laws.

招股说明书补充资料的电子副本可从A.G.P./联盟全球合作伙伴处获得，地址：纽约州纽约市麦迪逊大道590号28楼，邮编：10022，电话：（212）624-2060，电子邮件：prospectus@allianceg.com.根据适用加拿大证券法招股说明书要求的可用豁免，本次发行也可以在加拿大以私募方式进行。

No Canadian prospectus has been or will be filed in a province or territory of Canada to qualify the securities in connection with the Offering. The Company is relying upon the exemption set forth in Section 602.1 of the TSX Company Manual, which provides that the TSX will not apply its standards to certain transactions involving eligible interlisted issuers on a recognized exchange, such as Nasdaq..

加拿大一个省或地区尚未或将不会提交加拿大招股说明书，以使与本次发行相关的证券符合资格。本公司依赖《多伦多证券交易所公司手册》第602.1节规定的豁免，该节规定，多伦多证券交易所不会将其标准应用于涉及纳斯达克等公认交易所的合格中间上市发行人的某些交易。。

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction..

本新闻稿不构成出售要约或招揽购买要约，也不构成在根据任何州或司法管辖区的证券法注册或取得资格之前，在任何州或司法管辖区出售这些证券都是非法的。。

Related Party Transaction Disclosure

关联交易披露

The Company advises that a director of the Company may participate in the Offering. Participation by directors in the Offering is considered to be a “related party transaction” for purposes of Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (“MI 61-101”).

本公司建议本公司董事可参与本次发行。董事参与本次发行被视为多边文书61-101《特殊交易中保护少数股东证券持有人》（“MI 61-101”）中的“关联方交易”。

The Company is relying on the exemption from the formal valuation requirement in section 5.4 of MI 61-101 in reliance on sections 5.5(a) and 5.7(1)(a) of MI 61-101 as the participation of the directors is not expected to exceed 25% of the market capitalization of the Company. The Company notes that it will not file a material change report in respect of the related party transaction at least 21 days before the completion of the Offering.

公司依靠MI 61-101第5.5（a）和5.7（1）（a）节的规定，免除MI 61-101第5.4节的正式估值要求，因为董事的参与预计不会超过公司市值的25%。本公司注意到，至少在发行完成前21天，不会就关联交易提交重大变更报告。

The Company deems this circumstance reasonable in order to complete the issuance of the Offering in an expeditious manner..

公司认为这种情况是合理的，以便迅速完成发行。。

About BriaCell Therapeutics Corp.

关于BriaCell Therapeutics Corp。

BriaCell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. More information is available at https://briacell.com/.

BriaCell是一家临床阶段生物技术公司，开发新型免疫疗法以改变癌症护理。有关更多信息，请访问https://briacell.com/.

Safe Harbor

安全港

This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words.

本新闻稿包含具有重大风险和不确定性的“前瞻性声明”。除历史事实声明外，本新闻稿中的所有声明均为前瞻性声明。本新闻稿中包含的前瞻性陈述可以通过使用诸如“预期”、“相信”、“沉思”、“可能”、“估计”、“预期”、“打算”、“寻求”、“可能”、“可能”、“计划”、“潜在”、“预测”、“项目”、“目标”、“目标”、“应该”、“将会”、“将会”或这些词语或其他类似表达的否定词来识别，尽管并非所有前瞻性陈述都包含这些词语。

Forward-looking statements, including those about the Offering; and the contents of all such statements and current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate, including the ultimate use of the proceeds of the Offering, the terms and timing of the Offering, whether the Offering will be completed, or that the closing conditions to the Offering, including TSX and approval, will be satisfied.

前瞻性声明，包括有关发售的声明；以及所有此类声明的内容和当前预期，并受到难以预测的固有不确定性、风险和假设的影响。此外，某些前瞻性陈述基于对未来事件的假设，这些假设可能不准确，包括发行收益的最终用途、发行的条款和时间安排、发行是否会完成，或者发行的交割条件（包括TSX和批准）将得到满足。

These and other risks and uncertainties are described more fully under the heading “Risks and Uncertainties” in the Company's most recent Management’s Discussion and Analysis, under the heading 'Risk Factors' in the Company's most recent Annual Information Form, and under “Risks and Uncertainties” in the Company's other filings with the Canadian securities regulatory authorities and the U.S.

这些和其他风险和不确定性在公司最近的管理层讨论和分析中的“风险和不确定性”标题下，在公司最近的年度信息表中的“风险因素”标题下，以及在公司向加拿大证券监管机构和美国提交的其他文件中的“风险和不确定性”标题下进行了更全面的描述。

Securities and Exchange Commission, all of which are available under the Company's profiles on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. Forward-look.

证券交易委员会（Securities and Exchange Commission），所有这些都可以在SEDAR+网站（www.sedarplus.ca）和EDGAR网站（www.sec.gov.Forward look）的公司简介中找到。

Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.

多伦多证券交易所及其监管服务提供商（该术语在多伦多证券交易所的政策中定义）均不对本版本的充分性或准确性承担责任。

Contact Information

联系方式

Company Contact:

公司联系人：

William V. Williams, MD

William V.Williams，医学博士

President & CEO

总裁兼首席执行官

1-888-485-6340

1-888-485-6340

info@briacell.com

info@briacell.com

Media Relations:

媒体关系：

Jules Abraham

朱尔斯·亚伯拉罕

CORE IR

核心IR

julesa@coreir.com

julesa@coreir.com

Investor Relations Contact:

投资者关系联系人：

CORE IR

核心IR

investors@briacell.com

investors@briacell.com